Kintor Pharma Announces the First Patient Dosing in the U.S. Phase II Clinical Trial of Furitan for Hair Loss Treatment

SUZHOU, March 1, 2022 /PRNewswire/ -- On March 1, 2022, Beijing time, Kintor Pharma announced that its self-developed and potentially the world's first-of-its-kind furitan (KX-826) for the treatment of male androgen The US Phase II clinical trial of alopecia areata (AGA) has completed the first patient enrollment and dosing on February 28, 2022

As the most common type of hair loss, androgenetic alopecia accounts for more than 90% of the overall hair loss, and it plagues about 50 million to 60 million men and 30 million to 35 million women in the United States

Dr.

U.

The clinical trial (NCT05218642) is a randomized, double-blind, placebo-controlled, parallel-group study that plans to enroll 120 patients to evaluate the efficacy and safety of furatan in the treatment of male androgenetic alopecia

About Furitane

Furytan, an androgen receptor antagonist, is a potential first-in-class topical drug for the treatment of androgenetic alopecia and acne

Source: Kintor Pharmaceuticals

The original is abridged